mitoxantrone

Mitoxantrone is a synthetic anthracenedione antineoplastic agent used primarily in the treatment of certain cancers and multiple sclerosis. It acts as a type II topoisomerase inhibitor, intercalating into DNA and disrupting both DNA synthesis and repair in rapidly dividing cells. This mechanism underlies its cytotoxic effects against cancer cells. Mitoxantrone is also classified as an immunosuppressant when used for multiple sclerosis, where it inhibits the proliferation of certain immune system cells that contribute to nerve damage. The drug is administered intravenously and has been approved for use in acute nonlymphocytic leukemia (including acute myeloid leukemia), advanced hormone-refractory prostate cancer (often with prednisone), breast cancer, non-Hodgkin lymphoma, and relapsing or progressive forms of multiple sclerosis[1][2][3][5][8]. Developed in the 1980s as a less cardiotoxic alternative to anthracyclines due to its lack of an amino sugar structure[6], mitoxantrone remains on the WHO list of essential medicines.

Brand names

Novantrone

Other names

米托蒽醌Mitozantrone